Ferroptosis-centered Drug Response Information

General Information of the Drug (ID: ferrodrug0056)
Name
N-acetylcysteine
Synonyms
N-Acetyl-L-cysteine; acetylcysteine; 616-91-1; N-Acetylcysteine; mercapturic acid; Acetadote; Broncholysin; Mucomyst; L-Acetylcysteine; Fluimucetin; Fluimucil; Parvolex; N-Acetyl-cysteine; Fluprowit; Respaire; Acetein; Airbron; Fabrol; Mucosil; Flumucetin; Mucosolvin; Brunac; L-Cysteine, N-acetyl-; Fluimicil Infantil; N-Acetyl cysteine; Acetilcisteina; Acetylcysteinum; Syntemucol; Lysomucil; Mucofilin; acetyl cysteine; Exomuc; Inspir; Tixair; Mucolyticum Lappe; Mucolytikum Lappe; N-Acetyl-3-mercaptoalanine; (R)-2-Acetamido-3-mercaptopropanoic acid; Mucolyticum; Cetylev; Neo-fluimucil; Ac-Cys-OH; Cysteine, N-acetyl-, L-; Mucolyticum-Lappe; N-Acetyl-L-(+)-cysteine; NAC-TB; Acetyl-L-cysteine; component of Naxid; Mercapturic acid, (R)-; Fluatox; Fluimicil; Mucolator; Flumil; Mucret; (R)-mercapturic acid; Muco sanigen; Oristar nalc; (2R)-2-acetamido-3-sulfanylpropanoic acid; MUCOSIL-10; MUCOSIL-20; N-acetyi-l-cysteine; cysteine, N-acetyl-; L-alpha-Acetamido-beta-mercaptopropionic acid; CCRIS 3764; Mucocedyl; N-acetyl-(R)-cysteine; NSC 111180; UNII-WYQ7N0BPYC; WYQ7N0BPYC; HSDB 3003; EINECS 210-498-3; (2R)-2-Acetamido-3-sulfanyl-propanoic acid; Ilube (eye drops); N-A-C Sustain; NSC-111180; (r)-n-acetylcysteine; DTXSID5020021; CHEBI:28939; N-Acetyl-L-cysteine hydrochloride; RK-0202; DTXCID4021; MLS000028419; (R)-2-acetylamino-3-mercaptopropanoic acid; (2R)-2-acetylamino-3-sulfanylpropanoic acid; NSC111180; NCGC00022304-05; LNAC; SMR000058377; MFCD00004880; ACETYLCYSTEINE (II); ACETYLCYSTEINE [II]; ACETYLCYSTEINE (MART.); ACETYLCYSTEINE [MART.]; Ilube; N-acetylcystein; ACETYLCYSTEINE (EP MONOGRAPH); ACETYLCYSTEINE [EP MONOGRAPH]; N Acetylcysteine; ACETYLCYSTEINE (USP MONOGRAPH); ACETYLCYSTEINE [USP MONOGRAPH]; Acid, Mercapturic; Acetylcysteinum [INN-Latin]; CAS-616-91-1; Acetilcisteina [INN-Spanish]; N Acetyl L cysteine; N-Acetyl-N-Cysteine; SR-01000075439; DTXSID8048105; AcCys; N-acetyl-l-cys; Sodium 2-acetamido-3-mercaptopropionate; SC2; N-acetyl-L-cystein; Naxid (Salt/Mix); N-Acety-L-Cysteine; Acetyl Cysteine,(S); Acetylcysteine [USAN:USP:INN:BAN:JAN]; Opera_ID_452; MUCOMYST (TN); Acetylcysteine Ph. Eur.; Spectrum2_000086; Spectrum3_000287; Spectrum4_000137; Spectrum5_000764; CHEMBL600; NAC & TNF; ACETYLCYSTEINE [MI]; SCHEMBL5292; ACETYLCYSTEINE [INN]; ACETYLCYSTEINE [JAN]; Lopac0_000081; ACETYLCYSTEINE [HSDB]; ACETYLCYSTEINE [USAN]; BSPBio_001794; KBioGR_000554; MLS001076125; MLS006011563; ACETYLCYSTEINE [VANDF]; SPECTRUM1500105; SPBio_000012; ACETYL CYSTEINE [INCI]; ACETYLCYSTEINE [USP-RS]; ACETYLCYSTEINE [WHO-DD]; Acetylcysteine(N-acetylcysteine); BRONCHOLYSIN (MUCOLYTIC); DTXCID6028076; CHEBI:22198; GTPL10945; KBio3_001294; N-Acetyl-L-cysteine, USP grade; R05CB01; S01XA08; V03AB23; Acetylcysteine (JP17/USP/INN); HMS1920A11; HMS2091G11; HMS2234J22; HMS3260A04; HMS3655G11; HMS3715D03; HMS3884E04; HY-B0215; 2-Acetylamino-3-mercapto-propionate; ACETYLCYSTEINE [ORANGE BOOK]; Tox21_110877; Tox21_201078; Tox21_500081; acetylcysteine (n-acetyl-l-cysteine); BDBM50420190; CCG-38902; s1623; AKOS015841009; Tox21_110877_1; CCG-204176; DB06151; GS-3121; LP00081; SDCCGSBI-0050069.P002; (R)-2-Acetamido-3-mercaptopropanoicacid; NCGC00015086-04; NCGC00022304-03; NCGC00022304-04; NCGC00022304-06; NCGC00022304-07; NCGC00022304-08; NCGC00022304-17; NCGC00022304-23; NCGC00258631-01; NCGC00260766-01; AC-16071; AC-24117; BP-12854; SBI-0051272.P003; A0905; AM20100502; EU-0100081; SW199597-2; (2R)-2-acetylamino-3-mercapto-propionic acid; EN300-72028; A 7250; A-1100; C06809; D00221; L-Cysteine, N-acetyl- & Tumor necrosis factor; N-Acetyl-L-cysteine, BioXtra, >=99% (TLC); AB00051908_02; AB00382974-12; AB00382974_13; L-.alpha.-Acetamido-.beta.-mercaptopropionic acid; Q375613; J-507685; N-Acetyl-L-cysteine & Tumor necrosis factor (TNF); N-Acetyl-L-cysteine 100 microg/mL in Acetonitrile; SR-01000075439-1; SR-01000075439-3; SR-01000075439-5; BRD-K59058747-001-20-9; N-Acetyl-L-cysteine, cell culture tested, BioReagent; N-Acetyl-L-cysteine, Vetec(TM) reagent grade, 98%; F1905-7178; Z1143441555; CABC898A-E48B-4E13-9F72-98D0609A1854; N-Acetyl-L-cysteine, SAJ special grade, 98.0-102.0%; N-Acetyl-L-cysteine, Sigma Grade, >=99% (TLC), powder; Acetylcysteine, British Pharmacopoeia (BP) Reference Standard; Acetylcysteine, European Pharmacopoeia (EP) Reference Standard; Acetylcysteine, United States Pharmacopeia (USP) Reference Standard; N-Acetyl-L-cysteine, Pharmaceutical Secondary Standard; Certified Reference Material

    Click to Show/Hide
Status
Approved
Drug Type
Small molecular drug
Structure
Formula
C5H9NO3S
IUPAC Name
(2R)-2-acetamido-3-sulfanylpropanoic acid
Canonical SMILES
CC(=O)NC(CS)C(=O)O
InChI
InChI=1S/C5H9NO3S/c1-3(7)6-4(2-10)5(8)9/h4,10H,2H2,1H3,(H,6,7)(H,8,9)/t4-/m0/s1
InChIKey
PWKSKIMOESPYIA-BYPYZUCNSA-N
PubChem CID
12035
Full List of Ferroptosis Target Related to This Drug
Ferroptosis suppressor protein 1 (AIFM2)
 Target Info 
In total 1 item(s) under this Target
Experiment 1 Reporting the Ferroptosis-centered Drug Act on This Target [1]
Target for Ferroptosis Suppressor
Responsed Disease Ovarian dysfunction ICD-11: 5A80
 Disease Info 
Pathway Response Fatty acid metabolism hsa01212
Ferroptosis hsa04216
Cell Process Cell ferroptosis
Cell differentiation
In Vitro Model hPTs (Human placental tissues)
hPTs (Human placental tissues)
In Vivo Model
Adult Sprague-Dawley rats (70 days old) of both sexes were purchased from the Laboratory Animal Centre of Harbin Medical University, Harbin, China. Before the experiment, female rats were allowed to acclimatize for a minimum of 1 week and then were monitored daily by vaginal lavage to determine the stage of the estrous cycle as previously described (Zhanget al., 2016). Pregnancy was achieved by housing female rats on the night of proestrus with fertile males of the same strain at a 2:1 ratio. Confirmation of mating was performed the morning after by the presence of a vaginal plug, and this was considered as GD 0.5. The rats were sacrificed between 8:00 a.m. and 9:00 a.m. hours on GD 14.5.

    Click to Show/Hide
Response regulation Previous studies demonstrate that increased uterine and placental ferroptosis is associated with oxidative stress-induced fetal loss in a pre-clinical polycystic ovary syndrome (PCOS)-like rat model. N-acetylcysteine treatment results in increased mRNA expression of Aifm2, a negative regulator of GPX4-independent ferroptosis in the placenta. Moreover, NAC reverses HAIR-induced uterine and placental ferroptosis through activation of the Slc7a11/GSH/GPX4 axis.
Cystine/glutamate transporter (SLC7A11)
 Target Info 
In total 1 item(s) under this Target
Experiment 1 Reporting the Ferroptosis-centered Drug Act on This Target [1]
Target for Ferroptosis Suppressor
Responsed Disease Ovarian dysfunction ICD-11: 5A80
 Disease Info 
Pathway Response Fatty acid metabolism hsa01212
Ferroptosis hsa04216
Cell Process Cell ferroptosis
Cell differentiation
In Vitro Model hPTs (Human placental tissues)
In Vivo Model
Adult Sprague-Dawley rats (70 days old) of both sexes were purchased from the Laboratory Animal Centre of Harbin Medical University, Harbin, China. Before the experiment, female rats were allowed to acclimatize for a minimum of 1 week and then were monitored daily by vaginal lavage to determine the stage of the estrous cycle as previously described (Zhanget al., 2016). Pregnancy was achieved by housing female rats on the night of proestrus with fertile males of the same strain at a 2:1 ratio. Confirmation of mating was performed the morning after by the presence of a vaginal plug, and this was considered as GD 0.5. The rats were sacrificed between 8:00 a.m. and 9:00 a.m. hours on GD 14.5.

    Click to Show/Hide
Response regulation Previous studies demonstrate that increased uterine and placental ferroptosis is associated with oxidative stress-induced fetal loss in a pre-clinical polycystic ovary syndrome (PCOS)-like rat model. N-acetylcysteine treatment results in increased mRNA expression of Aifm2, a negative regulator of GPX4-independent ferroptosis in the placenta. Moreover, NAC reverses HAIR-induced uterine and placental ferroptosis through activation of the Slc7a11/GSH/GPX4 axis.
References
Ref 1 Suppression of uterine and placental ferroptosis by N-acetylcysteine in a rat model of polycystic ovary syndrome. Mol Hum Reprod. 2021 Nov 27;27(12):gaab067. doi: 10.1093/molehr/gaab067.